SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Swoboda, K. J.
Right arrow Articles by Simard, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swoboda, K. J.
Right arrow Articles by Simard, L. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Perspectives on Clinical Trials in Spinal Muscular Atrophy

Kathryn J. Swoboda, MD

Departments of Neurology and Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, swoboda{at}genetics.utah.edu

John T. Kissel, MD

Department of Neurology, Ohio State University School of Medicine, Columbus, Ohio

Thomas O. Crawford, MD

Departments of Neurology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

Mark B. Bromberg, MD, PhD

Departments of Neurology and Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah

Gyula Acsadi, MD, PhD

Departments of Neurology and Pediatrics, Wayne State University School of Medicine, Detroit, Michigan

Guy D'Anjou, MD

Division of Pediatric Neurology, Hôpital Sainte-Justine Montréal, Montréal, Québec, Canada

Kristin J. Krosschell, MA, PT

Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Sandra P. Reyna, MD

Departments of Neurology and Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah

Mary K. Schroth, MD

Department of Pediatrics, The University of Wisconsin School of Medicine, Madison, Wisconsin

Charles B. Scott, PhD

Louise R. Simard, PhD

Departments of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada

Spinal muscular atrophy is one of the most heterogeneous of the single-gene neuromuscular disorders. The broad spectrum of severity, with onset from the prenatal period to adulthood, presents unique challenges in the design and implementation of clinical trials. The clinical classification of subjects into severe (type 1), intermediate (type 2), and mild (type 3) subtypes has proved useful both in enhancing communication among clinicians internationally and in forging the collaborative development of outcome measures for clinical trials. Ideally, clinical trial design in spinal muscular atrophy must take into account the spinal muscular atrophy type, patient age, severity-of-affection status, nature of the therapeutic approach, timing of the proposed intervention relative to disease progression, and relative homogeneity of the cohort to be studied. Following is an overview of the challenges and opportunities, current and future therapeutic strategies, and progress to date in clinical trials in spinal muscular atrophy.

Key Words: spinal muscular atrophy • clinical trials • histone deacetylase inhibitors

Journal of Child Neurology, Vol. 22, No. 8, 957-966 (2007)
DOI: 10.1177/0883073807305665


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Hum Mol GenetHome page
L. M. Murray, S. Lee, D. Baumer, S. H. Parson, K. Talbot, and T. H. Gillingwater
Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy
Hum. Mol. Genet., February 1, 2010; 19(3): 420 - 433.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
R. A. Brumback
Child Neurologists Should Be Interested In Brain Tumors!
J Child Neurol, November 1, 2009; 24(11): 1338 - 1340.
[PDF]


Home page
NeurologyHome page
F. Deymeer, P. Serdaroglu, Y. Parman, and M. Poda
Natural history of SMA IIIb: Muscle strength decreases in a predictable sequence and magnitude
Neurology, August 26, 2008; 71(9): 644 - 649.
[Abstract] [Full Text] [PDF]



Advertisement